3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
41
Stomach Neoplasms
2
Neoplasm Metastasis
2
HER2-positive Breast Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Solid Tumors
1
Recurrence
1
Patient Preference
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Inflammatory Breast Neoplasms
1
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
1
HER2-Positive Primary Breast Cancer
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Cancer Metastatic
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
113
Carboplatin
99
Bevacizumab
59
pembrolizumab
56
liposomal doxorubicin
56
Gemcitabine
42
olaparib
39
Topotecan
33
niraparib
29
Nivolumab
21
Cisplatin
21
Doxorubicin
17
Cyclophosphamide
17
1-dodecylpyridoxal
16
Drug Therapy
15
Docetaxel
15
avelumab
13
Fulvestrant
11
oregovomab
10
Oxaliplatin
10
rucaparib
9
fludarabine
9
Injections
9
Fluorouracil
9
veliparib
8
mirvetuximab soravtansine
8
atezolizumab
8
Cetuximab
8
fluzoparib
7
cemiplimab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ovarian Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT04931342
2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2
Active not recruiting
176 enrolled